BRAIN CANCER

February 25th 2025

A study found that sonodynamic therapy showed no adverse events and demonstrated cancer cell death in 3 patients with glioblastoma.

February 19th 2025

The FDA has granted a priority review to dordaviprone for treating patients with recurrent H3K27M-mutant diffuse glioma, a population with limited treatment options.

February 11th 2025

The FDA approved mirdametinib for the treatment of adult and pediatric patients with neurofibromatosis type 1-associated plexiform neurofibromas.

January 17th 2025

FoundationOne CDx is now FDA-approved as the first companion diagnostic for tovorafenib, enabling targeted treatment for relapsed/refractory pediatric low-grade glioma with BRAF mutations or rearrangements.